TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12599448

Group type: EXPERIMENTAL
Intervention: BCG polysaccharides nucleic acid (BCG-PSN) 0.5 mg intramuscular injection, quaque die alterna, for 18 times
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BCG polysaccharides nucleic acid (BCG-PSN)
Number of subjects: 60
Study: 10450777

Group type: EXPERIMENTAL
Intervention: Ergonomic training program
Number of subjects: 627

Group type: COMPARATOR
Intervention: Reference group (no ergonomic training)
Number of subjects: 627
Study: 7847966

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined antegrade/retrograde cardioplegia (group A/R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 2278370

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with tramadol: loading dose 3 mg/kg, demand dose 30 mg, lock‐out time 5 min, concurrent infusion 5 mg/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous infusion (CI) with tramadol: loading dose 3 mg/kg, continuous infusion 0.35 mg/kg per h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both PCA and CI with tramadol
Number of subjects: 20
Study: 87315

Group type: EXPERIMENTAL
Intervention: Diffuse brain stimulation (DBS) administered just before sleep onset
Number of subjects: 7
Study: 31896036

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 784

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Prior GIB (both Apixaban and Warfarin)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Prior GIB <1 year before randomization (both Apixaban and Warfarin)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Apixaban vs. Warfarin
Number of subjects: 784
Study: 30852244

Group type: EXPERIMENTAL
Intervention: ACHIEVE behavioural weight loss intervention
Number of subjects: 0
Study: 28493742

Group type: EXPERIMENTAL
Intervention: Alcohol (target BrAC = .08g%)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: At-risk gamblers (n = 41)
Number of subjects: 162
Study: 25822241

Group type: EXPERIMENTAL
Intervention: Attribution Modification Training (AMT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 85
Study: 23318051

Group type: EXPERIMENTAL
Intervention: Glibenclamide (single morning dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glibenclamide and Physical exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12
Study: 21109365

Group type: EXPERIMENTAL
Intervention: Oral ketamine 65 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral ketamine 100 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral ketamine 150 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 20001132

Group type: EXPERIMENTAL
Intervention: Negative mood in intentional memorizing condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Positive mood in intentional memorizing condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Incidental memorizing condition (both moods)
Number of subjects: 50
Study: 17304396

Group type: EXPERIMENTAL
Intervention: Early-fed group (250 ml clear fruit juice 30 minutes postoperatively, unlimited solid food thereafter)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (clear feeds allowed after two hours, advanced to solids as tolerated)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Early-fed group
Number of subjects: 196
Study: 14574084

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol
Number of subjects: 273

Group type: COMPARATOR
Intervention: 5 mg bisoprolol
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 273

Group type: COMPARATOR
Intervention: bisoprolol
Number of subjects: 273
Study: 10792116

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg t.d.s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg t.d.s.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg t.d.s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg t.d.s.
Number of subjects: 0
Study: 8675093

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g daily for 9 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calcium supplementation and placebo
Number of subjects: 48
Study: 1378144

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg p.o.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Prazosin 2 mg p.o.
Number of subjects: 8
Study: 6731562

Group type: EXPERIMENTAL
Intervention: Resisted bilateral sanding
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Unresisted bilateral sanding
Number of subjects: 9
Study: 2416958

Group type: EXPERIMENTAL
Intervention: Azatadine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29264786

Group type: EXPERIMENTAL
Intervention: Multimodal drug injection (levobupivacaine 150 mg, ketorolac 30 mg, morphine 5 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Single anesthetic drug injection (levobupivacaine 150 mg)
Number of subjects: 64
Study: 27214383

Group type: EXPERIMENTAL
Intervention: CoQ10 300 mg loading dose 12 hours before procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no CoQ10)
Number of subjects: 100
Study: 24656645

Group type: EXPERIMENTAL
Intervention: BMMC (Bone Marrow Mononuclear Cell) transplantation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (vehicle injection)
Number of subjects: 104
Study: 22331951

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 503

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Switch to second AI (after washout period)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Overall AI therapy
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Younger age and taxane-based chemotherapy
Number of subjects: 503
Study: 20819882

Group type: EXPERIMENTAL
Intervention: Prednisone therapy (treated group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 24
Study: 18923577

Group type: EXPERIMENTAL
Intervention: Correct knowledge of carbohydrate intake
Number of subjects: 11

Group type: COMPARATOR
Intervention: False knowledge of carbohydrate intake (placebo)
Number of subjects: 11
Study: 15975732

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system
Number of subjects: 182

Group type: COMPARATOR
Intervention: Timeline Followback (TLFB)
Number of subjects: 182
Study: 14501386

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP) 10 i.v. 30-hour infusions every 2-4 weeks over a 24-week period (n = 28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no ATP, n = 30)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP) in weight-losing patients with stage IIIB NSCLC
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group in weight-losing patients with stage IIIB NSCLC
Number of subjects: 58
Study: 10825790

Group type: EXPERIMENTAL
Intervention: Salbutamol alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Salbutamol with ipratropium bromide
Number of subjects: 40
Study: 8875972

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 137
Study: 2059002

Group type: EXPERIMENTAL
Intervention: Computer network support for caregivers; details on dosage and duration not available.
Number of subjects: 0
Study: 6650699

Group type: EXPERIMENTAL
Intervention: Tacrine (45-90 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30146405

Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX (8000 PFU)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX (25000 PFU)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Frozen VARIVAX (10,000 PFU)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX with M-M-RII
Number of subjects: 958

Group type: COMPARATOR
Intervention: Frozen VARIVAX with M-M-RII
Number of subjects: 958
Study: 29564844

Group type: EXPERIMENTAL
Intervention: 9x20-sec level strides (105%vVO2max; 1% gradient) with 60 s of recovery
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 6x6-sec uphill strides (105%vVO2max; 5% gradient) with 60 s of recovery
Number of subjects: 11

Group type: COMPARATOR
Intervention: 7 min at 60%vVO2max as control condition
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All WU conditions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Uphill and level WUs
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control WUs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-intensity WUs
Number of subjects: 11
Study: 26758377

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 2834

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 2834
Study: 24661819

Group type: EXPERIMENTAL
Intervention: Living with others
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Participants enrolled in the United States/Canada
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Taking more (7+) prescription medications
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Scoring lower on the Stroke Specific Quality of Life scale
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Taking fewer (0-2) medications
Number of subjects: 2374
Study: 22658437

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) light box emitting 10,000 lx
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low-Intensity (LI) light box emitting 2000 lx
Number of subjects: 101
Study: 20206429

Group type: EXPERIMENTAL
Intervention: 1,200 mg oxaprozin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18283734

Group type: EXPERIMENTAL
Intervention: Interferon tablets 4000 IU
Number of subjects: 0
Study: 16275250

Group type: EXPERIMENTAL
Intervention: Modified cryopreservation method
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard cryopreservation method
Number of subjects: 201
Study: 12078365

Group type: EXPERIMENTAL
Intervention: Computerised decision support tool for stroke prevention in AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and testing phase for GPs and practice nurses
Number of subjects: 0
Study: 9885387

Group type: EXPERIMENTAL
Intervention: levodopa benzeraside 2 mg/kg 3 times per day for 1 week
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: levodopa benzeraside
Number of subjects: 32
Study: 9081359

Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg/day up to 400 mg/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Amphotericin B (0.8 mg/kg/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 112
Study: 1516345

Group type: EXPERIMENTAL
Intervention: Iomeprol 350
Number of subjects: 98

Group type: COMPARATOR
Intervention: Iopamidol 340
Number of subjects: 98
Study: 6746962

Group type: EXPERIMENTAL
Intervention: Constrained thought
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unconstrained thought
Number of subjects: 20
Study: 31469703

Group type: EXPERIMENTAL
Intervention: Occlusive technique
Number of subjects: 13

Group type: COMPARATOR
Intervention: Drip technique
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 13
Study: 29061746

Group type: EXPERIMENTAL
Intervention: Dispersible-tablet formulation of dihydroartemisinin/piperaquine phosphate (DHA/PQP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Crushed tablets (Eurartesim)
Number of subjects: 300
Study: 27092397

Group type: EXPERIMENTAL
Intervention: Peer support and mindfulness program
Number of subjects: 275

Group type: COMPARATOR
Intervention: Existing mental health resources (control)
Number of subjects: 275
Study: 24845800

Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Number of subjects: 121982

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121982
Study: 22555225

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study: 21054881

Group type: EXPERIMENTAL
Intervention: Austrian disease management programme (DMP) for diabetes mellitus type 2
Number of subjects: 1489
Study: 18303130

Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 0
Study: 16003858

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 12438897

Group type: COMPARATOR
Intervention: Tampon sampling for 10 seconds
Number of subjects: 309

Group type: COMPARATOR
Intervention: Tampon sampling for 1 hour
Number of subjects: 309

Group type: COMPARATOR
Intervention: Tampon sampling for 4 hours
Number of subjects: 309

Group type: COMPARATOR
Intervention: Tampon sampling overnight
Number of subjects: 309

Group type: COMPARATOR
Intervention: Swab sampling
Number of subjects: 309
Study: 10435261

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach and Relapse Prevention
Number of subjects: 166
Study: 8829715

Group type: EXPERIMENTAL
Intervention: Behavioral family management (BFM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study: 2113671

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 1 and 3 months)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 2 and 4 months)
Number of subjects: 141
Study: 498916

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium methylglucamine diatrizoate (10:66)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrizamide and Sodium methylglucamine diatrizoate
Number of subjects: 0
Study: 31484659

Group type: EXPERIMENTAL
Intervention: 9cUAB30 (n = 8)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (n = 2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 9cUAB30 (20 mg dose level)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 9cUAB30 (240 mg dose level)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 9cUAB30
Number of subjects: 53
Study: 29250974

Group type: EXPERIMENTAL
Intervention: Moistened misoprostol (200 µl distilled water, 2 × 200 μg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dry misoprostol (2 × 200 μg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Moistened misoprostol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dry misoprostol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Moistened and dry misoprostol
Number of subjects: 46
Study: 26271371

Group type: EXPERIMENTAL
Intervention: DRSP/EE
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DRSP/E2
Number of subjects: 50

Group type: COMPARATOR
Intervention: DRSP/EE and KTZ
Number of subjects: 50

Group type: COMPARATOR
Intervention: DRSP/E2 and KTZ
Number of subjects: 50
Study: 24429091

Group type: EXPERIMENTAL
Intervention: Nasogastric hydration
Number of subjects: 759

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 759
Study: 22403981

Group type: EXPERIMENTAL
Intervention: Intra-oral hearing device (SoundBite)
Number of subjects: 22
Study: 19843034

Group type: EXPERIMENTAL
Intervention: Strain-Encoded MRI
Number of subjects: 69
Study: 16393740

Group type: EXPERIMENTAL
Intervention: Enhanced gender‐specific and culturally specific HIV intervention
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Motivation intervention arm
Number of subjects: 333

Group type: COMPARATOR
Intervention: NIDA standard condition
Number of subjects: 333
Study: 15289187

Group type: EXPERIMENTAL
Intervention: CPU care
Number of subjects: 972

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 972
Study: 11345378

Group type: EXPERIMENTAL
Intervention: Oral pharmacologic treatment with flecainide (group A, n = 23)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hybrid treatment (catheter ablation of the inferior vena cava‐tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Catheter ablation of the isthmus only (group C, n = 24)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (group D, n = 37)
Number of subjects: 71
Study: 9230767

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of l-menthol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nasal inhalation of strawberry-flavored air
Number of subjects: 11
Study: 8061442

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at standard dose (0.1 mmol/kg)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at higher dose (0.3 mmol/kg)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Both doses of gadodiamide injection
Number of subjects: 289
Study: 3377272

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1200 mg daily in addition to basic therapy (antihypertensives, antidiabetic drugs, etc)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline or other hemorheologic medication)
Number of subjects: 100
Study: 4919118

Group type: EXPERIMENTAL
Intervention: Nutrizym
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pancrex V forte
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nutrizym core alone
Number of subjects: 12
Study: 30971173

Group type: EXPERIMENTAL
Intervention: A-FFIP intervention (2 hours/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 20
Study: 30403428

Group type: EXPERIMENTAL
Intervention: Eccentric contractions (ECC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Concentric contractions (CON)
Number of subjects: 14
Study: 28011798

Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis with ECG recording based on levels; participants with NT-proBNP ≤ 125 pg/L will have a single one lead ECG recording, and those with NT-proBNP ≥ 125 pg/L will record ECG for 30 seconds at least twice daily for 2 weeks.
Number of subjects: 28712

Group type: COMPARATOR
Intervention: Control group with standard care without screening.
Number of subjects: 28712
Study: 28844541

Group type: EXPERIMENTAL
Intervention: MEDI8852 (250, 750, 1,500, or 3000 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MEDI8852 (750 mg and 3000 mg)
Number of subjects: 40
Study: 23504050

Group type: EXPERIMENTAL
Intervention: 250 mcg IFNB‐1b
Number of subjects: 0
Study: 21521860

Group type: EXPERIMENTAL
Intervention: Generic levetiracetam formulations
Number of subjects: 4

Group type: COMPARATOR
Intervention: Keppra (brand name levetiracetam)
Number of subjects: 4
Study: 19745646

Group type: EXPERIMENTAL
Intervention: Antipsychotics (neuroleptics and atypicals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17928597

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg per square meter) after doxorubicin plus cyclophosphamide
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Doxorubicin (60, 75, or 90 mg per square meter) plus cyclophosphamide (600 mg per square meter)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Observation (control group) after doxorubicin plus cyclophosphamide
Number of subjects: 1500
Study: 15519779

Group type: EXPERIMENTAL
Intervention: Oral sucralfate (3 g suspension, twice daily)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 11681650

Group type: EXPERIMENTAL
Intervention: AERx (0.45 mg total)
Number of subjects: 4

Group type: COMPARATOR
Intervention: PARI (3.0 mg nebulized until dry)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AERx
Number of subjects: 4
Study: 9627590

Group type: EXPERIMENTAL
Intervention: Acellular vaccines (two three-component vaccines)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine
Number of subjects: 1572
Study: 7836714

Group type: COMPARATOR
Intervention: Contractors
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hypocontractors
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Gallstone volume
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (0.1 nM-1 microM)
Number of subjects: 250
Study: 2971233

Group type: EXPERIMENTAL
Intervention: Manipulation of the sacroiliac joint (Experimental Group, n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control Group, n = 10)
Number of subjects: 26
Study: 29196153

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus IP 174178 (Lc)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 26771781

Group type: EXPERIMENTAL
Intervention: Thiamine 200 mg twice daily for 7 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25015597

Group type: EXPERIMENTAL
Intervention: Distilled water (n = 158)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Saline solution (n = 162)
Number of subjects: 328
Study: 23510945

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis alert to Attending Physician before discharge
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Control group (no alert)
Number of subjects: 2513

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis alert group
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2513
Study: 20466437

Group type: EXPERIMENTAL
Intervention: 1000 mg eicosapentaenoic acid (EPA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1000 mg eicosapentaenoic acid (EPA) + 20 mg fluoxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 20 mg fluoxetine (control)
Number of subjects: 42